ccl22  (R&D Systems)

Journal: Cell Biology and Toxicology

Article Title: SENP3 mediated DeSUMOylation of macrophage derived CCL17 accelerates atherosclerosis via regulation of Treg

doi: 10.1007/s10565-025-10099-3

Figure Lengend Snippet: Macrophages stimulated by oxLDL affect the chemotaxis of Treg through CCL17 and CCL22 competition. Macrophages were stimulated with oxLDL, and Treg cells were co-cultured with macrophage supernatant. A Immunofluorescence detection of co-localization of CCL22 and macrophages (CD68) in plaque tissue of AS mice. B The content of CCL22 in the supernatant of macrophages was detected by ELISA. C Transwell detected the effect of macrophages on the chemotaxis of Treg. ( D - E ) Transwell detected the migration of Treg cells. * p < 0.05, ** p < 0.01, *** p < 0.001. N = 3

Article Snippet: Prior to the transwell migration assay, the induced Tregs were treated with recombinant mouse CCL17 (MCE, HY-P71891A) or recombinant mouse CCL22 (MCE, HY-P7248) or anti-CCL17 (R&D, Catalog #: MAB529) and anti-CCL22 antibodies (R&D, Catalog #: MAB529).

Techniques: Chemotaxis Assay, Cell Culture, Immunofluorescence, Enzyme-linked Immunosorbent Assay, Migration

Journal: Frontiers in pharmacology

Article Title: Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma.

doi: 10.3389/fphar.2023.1092767

Figure Lengend Snippet: FIGURE 3 PLX3397 and αCSF1R reduce TAM-derived CCL22 that affect T cell recruitment. (A) 15 days after treatment began, serum of mice in each group was collected and the CBA method was used to detect Th1/Th2/Th17-related inflammatory factors, n = 10. (B) 15 days after treatment began, serum chemokine levels of CCL2, CCL22, CXCL10 and CXCL9 were detected by ELISA kit, n = 10. (C) Serum levels of CCL22 at day 0,5,10,15 and 20 during the development of murine subcutaneous tumors, with treatment starting at day 7 after tumor inoculation, n = 10. (D) Macrophages, T cells and CD45−

Article Snippet: In the CCL22 compensation experiment, 100 ng/mice of recombinant Mouse CCL22/MDC Protein (439-MD-025, R&D Systems, MN, United States) was given through i. v. Injection at the time of PLX3397 treatment.

Techniques: Derivative Assay, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in pharmacology

Article Title: Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma.

doi: 10.3389/fphar.2023.1092767

Figure Lengend Snippet: FIGURE 4 The combination of αPD-1 and PLX3397 showed better therapeutic effect, and αPD-1 further promoted the polarization switch of TAM. (A) The change of tumor volume within 15 days after treatment began, n = 5. LLC subcutaneous tumor model was developed and the treatment experiment was conducted according to the description in the method; (B) Survival rate of different treatment groups after PLX3397 combined with αPD-1, n = 5; (C) The mice were sacrificed on 40 days after treatment began, the subcutaneous tumors were collected, photographed and (D) the tumors were weighed; (E) The proportion of CD8+ T cells/Treg cells was analyzed by flow cytometry at day 40 after treatment began; (F) One of two independent αPD-1 treatment experiments, n = 5, (G) the tumors of 40 DPT were weighed and (H) The proportion of CD8+ T cells/Treg cells was analyzed by flow cytometry. (I) Representative figure of FISH was used to identify Ccl22 transcription in tumor and (J) integrated optical density statistical results. (K) qPCR was used to analyze the transcription of Ccl22 in purified tumor macrophages on day 40 after treatment. (L) The transcriptional levels of Arg1 and Tgfb1 in separated TAM on day 15 after treatment began were analyzed by qPCR.

Article Snippet: In the CCL22 compensation experiment, 100 ng/mice of recombinant Mouse CCL22/MDC Protein (439-MD-025, R&D Systems, MN, United States) was given through i. v. Injection at the time of PLX3397 treatment.

Techniques: Cytometry